Tocilizumab

托珠单抗

Report date: 2026/05/26 20:00:28
First In Class

Base Information

Drug NameTocilizumab
Drug Alias NameAtlizumab托西利珠单抗Tocilizumabum托西珠单抗Actemra +[16] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-6 receptor alpha subunit antagonistsInterleukin-6 receptor subunit beta antagonists
TargetsInterleukin-6 receptor alpha subunitInterleukin-6 receptor subunit beta
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Non-radiographic axial spondyloarthritisPolyarticular Juvenile Idiopathic Arthritis +[60] 
Global Approved IndicationsArthritis, RheumatoidArthritis, Juvenile
Approved Indications in ChinaArthritis, RheumatoidArthritis, Juvenile
Original Approved Country/TerritoryJapan
Original Approved Date2005/04/11
Country/TerritoryCzechiaBelgiumBulgaria +[62] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesChugai Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesFresenius AgRoche Diagnostic LtdRoche Pharma Ag +[24] 
Inactive CompaniesBrazilian Clinical Research InstituteFederal University Of Sao PauloBiogipuzkoa Health Research Institute +[23] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Polyarticular Juvenile Idiopathic ArthritisIschemic Stroke +[23] 
Inactive IndicationsNon-radiographic axial spondyloarthritisSolid tumoursFever +[37] 

Other Information

ATC CodeL04AC07
Related LinksWikipediaDrugBankKEGG